This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (538) Cancer and Clinical Trials (19)

Published on in Vol 7, No 7 (2018): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11191, first published .
Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Authors of this article:

Isao Hara1 Author Orcid Image ;   Shimpei Yamashita1 Author Orcid Image ;   Satoshi Nishizawa1 Author Orcid Image ;   Kazuro Kikkawa1 Author Orcid Image ;   Toshio Shimokawa2 Author Orcid Image ;   Yasuo Kohjimoto1 Author Orcid Image
Article Authors Cited by (7) Tweetations (1) Metrics

Journals

  1. Peter M, Bilenky M, Isserlin R, Bader G, Shen S, De Carvalho D, Hansen A, Hu P, Fleshner N, Joshua A, Hirst M, Bapat B. Dynamics of the Cell-Free DNA Methylome of Metastatic Prostate Cancer During Androgen-Targeting Treatment. Epigenomics 2020;12(15):1317 View
  2. Ferriero M, Mastroianni R, De Nunzio C, Cindolo L, Calabrò F, Tema G, Leonardo C, Flammia R, Tuderti G, Anceschi U, Brassetti A, Giacinti S, Guaglianone S, Ghahhari J, Schips L, Tubaro A, Gallucci M, Simone G. Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World Journal of Urology 2020;38(7):1757 View
  3. Cardoso P, Santos C, Costa F, Rocha-Gonçalves F. Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Global Journal on Quality and Safety in Healthcare 2020;3(2):65 View
  4. Scailteux L, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E. Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014–2018 French Population Study (the SPEAR Cohort). American Journal of Epidemiology 2021;190(3):413 View
  5. Lin Y, Huang Y, Liu C, Lee T, Chen M, Chien Y. Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide. Frontiers in Pharmacology 2021;12 View
  6. Cheng H, Wang Y, Liu C, Wu T, Chen S, Chen M. Development and Verification of a Prostate Cancer Prognostic Signature Based on an Immunogenomic Landscape Analysis. Frontiers in Oncology 2021;11 View
  7. Gopukumar D, Menon N, Schoen M. Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach. JMIR Medical Informatics 2024;12:e59480 View